Market research
ZENA.TO Zenabis Global Inc
TO CAD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 148M
- P/E ratio
- Not available
- Analyst target
- 0.15
- Dividend yield
- Not available
- Beta
- 0.58
Profile
Instrument facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA98936N1024
- Market cap
- 148M
- P/E ratio
- Not available
- Analyst target
- 0.15
- Dividend yield
- Not available
- Beta
- 0.58
About
About Zenabis Global Inc
Zenabis Global Inc. engages in the cultivation and sale of medical and adult-use recreational cannabis in Canada and internationally. The company produces and markets strains of dried cannabis under the Zenabis, Namaste, and Re-üp brands; and various oil-based cannabis products. It has 111,200 kg of licensed cannabis cultivation space in three licensed facilities in Canada. The company is headquartered in Vancouver, Canada. As of June 1, 2021, Zenabis Global Inc. operates as a subsidiary of HEXO Corp.
Research context
Zenabis Global Inc appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ZENA.TO discussion.
5 years, 6 months ago
Zenabis Global Inc is currently in a long term uptrend where the price is trading 45.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Zenabis Global Inc's total revenue rose by 32.6% to $24M since the same quarter in the previous year.
Its net income has increased by 82.6% to $-17M since the same quarter in the previous year.
Finally, its free cash flow grew by 96.4% to $-4M since the same quarter in the previous year.
Based on the above factors, Zenabis Global Inc gets an overall score of 5/5.